"There will be no MBA school analysis that makes any of these (deals) look intelligent," said Erik Gordon, associate dean at the Howe School of Technology Management in the Stevens Institute of Technology in New Jersey. "It's simply a bet of blockbusters coming out of the purchased pipelines."
Story
1 comment:
Absolutely right. Big pharma has no choice but to take big risks. The companies that handle risk best win because there is no way to eliminate it.
Post a Comment